A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: NSCLC|Breast Cancer
Interventions: DRUG: Poziotinib
Sponsor: Spectrum Pharmaceuticals, Inc